Assignee
SHANGHAI HENLIUS BIOTECH INC
CN·6 granted patents·21 pending applications·3 citations·filing 2019–2025
Top patents by PatentIndex Score
27 records- 0188US12415858B2Anti-tigit antibodies, multispecific antibodies comprising the same, and methods of using the sameSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Granted Sep 16, 2025·1 cites·21 claims
- 0281US11274155B2Anti-PD-L1 antibodies and variantsSHANGHAI HENLIUS BIOTECH INC·Filed 2019·Granted Mar 15, 2022·2 cites·13 claims
- 0366US11618786B2Anti-PD-L1 antibodies and variantsSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Granted Apr 4, 2023·0 cites·23 claims
- 0466US2024383995A1Anti-ox40 antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2024·Application pending·0 cites
- 0566US2024383996A1Anti-ox40 antibodies, multispecific antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2024·Application pending·0 cites
- 0664US2026042734A1Heterocyclic ring-substituted aromatic compound, preparation method therefor, and use thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2025·Application pending·0 cites
- 0763US11685783B2Anti-PD-1 antibodiesSHANGHAI HENLIUS BIOTECH INC·Filed 2021·Granted Jun 27, 2023·0 cites·15 claims
- 0863US2025019459A1Anti-msln antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2024·Application pending·0 cites
- 0962US11261255B2Anti-epidermal growth factor receptor (EGFR) antibodiesSHANGHAI HENLIUS BIOTECH INC·Filed 2020·Granted Mar 1, 2022·0 cites·14 claims
- 1061US2024043558A1Anti-gpc3 antibodies, multispecific antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2023·Application pending·0 cites
- 1161US2024043559A1Anti-gpc3 antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2023·Application pending·0 cites
- 1260US11028173B2Anti-PD-1 antibodiesSHANGHAI HENLIUS BIOTECH INC·Filed 2019·Granted Jun 8, 2021·0 cites·18 claims
- 1360US2023340098A1Anti-garp/tgf-beta antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2023·Application pending·0 cites
- 1460US2024076395A1Anti-cd137 constructs and uses thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1559US2023067770A1Anti-cd137 constructs, multispecific antibody and uses thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1659US2023060388A1Anti-tigit antibodies, multispecific antibodies comprising the same, and methods of using the sameSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1759US2022403040A1Anti-cd137 constructs, multispecific antibody and uses thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1858US2023134580A1Anti-tigit antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1956US2025320297A1Anti-pdl1 antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2025·Application pending·0 cites
- 2055US2023279110A1Anti-cd47 antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2023·Application pending·0 cites
- 2153US2025326848A1Anti-pdl1 antibodies, multispecific antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2025·Application pending·0 cites
- 2251US2023074657A1Anti-lag3 monoclonal antibody, and preparation method therefor and use thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2021·Application pending·0 cites
- 2350US2026076959A1Combination product, salt, and use thereof in treating neurodegenerative diseases or disordersSHANGHAI HENLIUS BIOTECH INC·Filed 2025·Application pending·0 cites
- 2450US2023192832A1Pharmaceutical formulation comprising bevacizumabSHANGHAI HENLIUS BIOTECH INC·Filed 2021·Application pending·0 cites
- 2550US2026078118A1Combined product, salt and use thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2025·Application pending·0 cites
- 2650US2023048612A1Programmed cell death receptor 1 antibody formulation and use thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2021·Application pending·0 cites
- 2749US2025243278A1Anti-b7h3 antibodies and methods of useSHANGHAI HENLIUS BIOTECH INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI HENLIUS BIOTECH INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →